Skip to main content

Tuberculosis: The Disease & Vaccines

Tuberculosis: The Disease & Vaccines

Prior to the COVID-19 pandemic, tuberculosis (TB) killed more people in the world than any single infectious disease. In 2021, SARS-CoV-2, which causes COVID-19, surpassed TB. However, it is anticipated that as we move away from the pandemic, newer data will return the deadliest infection title to TB. Each year, about 10 million people around the world are infected with TB and about 1.2 million die. This statistic becomes even more heartbreaking when you realize that TB is both preventable and curable. 

Cases of TB occur in the U.S. each year, but most are diagnosed in people not born in the U.S. Annual cases have been going up since 2021, increasing from about 7,900 cases in 2021 to about 10,350 cases in 2024. The number of deaths each year has been between 500 and 600.

The TB vaccine is rarely used in the U.S. In most other countries, the vaccine for tuberculosis, known as the BCG vaccine, is used more commonly because of the frequency of disease.

The disease

What is tuberculosis?

Tuberculosis (TB) is caused by a bacterium, known as Mycobacterium tuberculosis. The infection primarily attacks the lungs. The bacteria are so destructive that infected people commonly cough up mucus and blood. Children less than 5 years of age can have a severe, often fatal, form of TB, called "miliary" TB. Miliary TB results when the bacteria spread to many parts of the body, including the lining of the brain (meninges).

TB is highly contagious. The bacteria spreads through coughing, sneezing, talking and singing. Many people who are infected don't get sick right away. Instead, the bacteria live without reproducing or causing symptoms for years, even decades. When someone has the inactive bacteria in their body, they have “latent TB.” If the bacteria reactivate, the person will develop lung disease and the characteristic cough associated with TB. This is called “active TB.”

What are the symptoms of TB?

People with latent TB do not usually have symptoms unless the bacteria reactivate to cause active TB.

Active TB causes different symptoms depending on the area of the body where the infection is occurring. In most people the infection occurs in their lungs, causing:

  • Coughing that lasts for weeks and contains blood or mucus
  • Chest pain
  • Weakness and fatigue
  • Loss of appetite and weight loss
  • Chills, fever or night sweats

Notably, children tend to have less severe symptoms, such as a cough that does not produce blood or mucus.

Other parts of the body that can be affected include:

  • Lymph nodes, causing hard, painless red- or purple-colored sores under the skin
  • Kidneys, causing blood in urine
  • Lining of the brain, causing inflammation (meningitis), headache or confusion
  • Spine, causing back pain
  • Voice box or larynx, causing hoarseness

Who is at risk for TB?

Anyone can be infected with the bacteria that cause TB, but those at increased risk for an infection include:

  • People born in a country with large numbers of infected people
  • People in congregate living facilities, including homeless shelters and prisons
  • People living with an infected person who cannot be treated with antibiotics or who is infected with antibiotic resistant types of TB

People with latent TB, meaning the Mycobacterium tuberculosis bacteria are living in their body but not reproducing, are at the greatest risk for active TB. It is estimated that about 2 billion people around the world have latent TB infections. In the U.S., the estimate is about 13 million people. 

Within this group of people living with the bacteria, some are more likely to develop active disease, including:

  • People recently infected with the bacteria
  • People with weakened immune systems from treatments or conditions, such as HIV, diabetes and cancer

How is TB diagnosed?

People can be tested for TB in two ways:

  • TB skin test A small amount of material is put under a person’s skin, and they return to the healthcare provider in two to three days to have the area evaluated for a reaction. This test is sometimes called a “purified protein derivative,” or PPD test.
  • TB blood test — A small blood sample is drawn from the person. The blood is mixed with a small amount of TB proteins at the lab to see how immune system cells in the blood respond. 

If a person was vaccinated against TB, the blood test is the recommended choice because the skin test is more likely to result in a false positive. While most people in the U.S. do not get vaccinated against TB, many people in other countries do.

If a person’s TB test is positive, they will be recommended to get a chest X-ray to determine if their lungs show evidence of an active TB infection. 

How is TB treated?

About 5 or 10 of every 100 people living with latent TB will go on to develop active TB during their life if they are not treated. But not all people are recommended for treatment. Usually those at highest risk for development of active disease are treated with a series of antibiotics. This decision is usually made in concert with public health officials or healthcare providers with experience treating TB because the treatment is long (months), requires several different medications, and often results in side effects. Concerns about antibiotic resistance, which is when the bacteria change so they are no longer stopped by the antibiotic treatment, are also a factor.

People with active TB are treated with antibiotics. They usually take multiple medications for a period of four to six months or longer. If people with active TB do not follow the instructions for these medications, they may get sick again, and the bacteria may become resistant to treatment.  

Is TB increasing in the U.S.?

Cases of TB started to increase in the U.S. in the 1980s when the HIV epidemic began because people with HIV have weakened immune systems. As we got better at treating HIV, cases of TB started to slowly decline, beginning around 1993. A larger decrease was observed during the COVID-19 pandemic, likely due to decreased interactions among people. But since 2021, cases have been increasing each year. 

Worried woman

Tuberculosis (TB) Q&A

TB Special Topics Q&A

The vaccine

How is the TB vaccine made?

The TB vaccine has been around since the early 1920s. The scientists who developed it were Albert Calmette and Camille Guérin, so the vaccine is called the Bacillus Calmette-Guérin, or BCG, vaccine. It is made by weakening a strain of bacteria similar to the one that causes TB. This strain of bacteria, called Mycobacterium bovis, was first isolated in cows and is similar enough to the strain that infects people, Mycobacterium tuberculosis, that vaccination with the cow strain protects against disease caused by the human strain.

Does the TB vaccine have side effects?

Soreness at the site of the injection is common. About 3 of every 10,000 people who get the TB vaccine develop painful swelling under the arm.

Who should get the TB vaccine?

Few people in the U.S. are recommended to get the TB vaccine. Those include: 

  • Children who are negative for TB but have ongoing exposure to the bacteria and can’t take long-term preventive medications. Ongoing exposure is considered as living with someone with TB who is untreated or infected with a strain that is resistant to all antibiotics.
  • Individual healthcare workers in settings with high rates of TB-positive patients infected with strains that are antibiotic resistant, ongoing spread of antibiotic-resistant strains, or unsuccessful infection control efforts. Individual risk-benefit assessments are recommended for healthcare workers in these settings.

Only a small number of people in the U.S. fall into these categories. Decisions regarding this vaccine are typically made in consultation with a local TB control program. The TB vaccine is given as a single shot.

Other questions you might have

Since TB is increasing in the U.S., why isn't the vaccine recommended for everyone at risk of catching the disease?

The TB vaccine is good at protecting against miliary TB, the severe form of disease found in young children, but it is not as good at protecting against the lung infection commonly found in adolescents and adults. Because miliary TB is very uncommon in the U.S., we do not routinely use the TB vaccine. The U.S. is one of only two countries in the world that have never routinely used the TB vaccine. The Netherlands is the other. Several countries previously had routine recommendations but changed them to target high-risk individuals only. 

If we are not routinely using the TB vaccine, what are we doing to stop the spread of TB in the U.S.?

The U.S. does two things to stop the spread of TB. First, people infected with the bacteria that cause TB are identified by testing. Second, people with active TB are treated with antibiotics effective against the bacteria. Some people with latent TB are also treated with antibiotics.

Relative risks and benefits

Do the benefits of the TB vaccine outweigh its risks?

The TB vaccine is not highly effective at preventing lung infections caused by Mycobacterium tuberculosis bacteria. For this reason, the vaccine is only recommended for a small subset of those in contact with someone with TB. On the other hand, the TB vaccine has no serious side effects. So, for the small subset of people recommended to get the vaccine, the benefits clearly outweigh the risks.

Disease risks

  • Coughing that lasts for weeks and contains blood or mucus.
  • Antibiotics don’t always work.
  • Children can develop miliary TB in which the bacteria spread to other parts of the body, including the lining of the brain.
  • Disease can be fatal.

Vaccine risks

  • Pain at the injection site
  • Painful, swelling under the arm (3 in 10,000 people)
  • May not protect against more common type of tuberculosis

Resources

We are TB is a support group for people and families affected by TB.

References

Orenstein W, Offit PA, Edwards K, and Plotkin SA. Tuberculosis Vaccines in Vaccines, 8th Edition. 2024, 1158-1176.

World Health Organization. Tuberculosis, updated Nov. 13, 2025.

Schmit KM, Wansaula Z, Pratt R, Price SF, Langer AJ. Tuberculosis-United States, 2016. MMWR Morb Mortal Wkly Rep 2017; 66:289-296.

Reviewed by Paul A. Offit, MD, on Jan. 29, 2026

Jump back to top